Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan

被引:172
|
作者
Miyakawa, Shuichi [1 ]
Ishihara, Shin [1 ]
Horiguchi, Akihiko [1 ]
Takada, Tadahiro [2 ]
Miyazaki, Masaru [3 ]
Nagakawa, Takukazu [4 ]
机构
[1] Fujita Hlth Univ, Dept Biliary & Pancreat Surg, Toyoake, Aichi 4701192, Japan
[2] Teikyo Univ, Dept Surg, Tokyo 173, Japan
[3] Grad Sch Med, Dept Gen Surg, Chiba, Japan
[4] Fukuno Hosp, Nanto, Toyama, Japan
来源
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY | 2009年 / 16卷 / 01期
关键词
Biliary tract cancer; Statistics registry; 5-year survival; Stage of disease; Lymph node metastasis; LONG-TERM SURVIVAL; AMPULLARY CARCINOMAS; GALLBLADDER CANCER; SURGERY; CHOLANGIOCARCINOMA; GUIDELINES; MANAGEMENT; RECURRENCE; VATER; EXPERIENCE;
D O I
10.1007/s00534-008-0015-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The results from the Japanese Biliary Tract Cancer Statistics Registry from 1988 to 1998 were reported in 2002. In the present study, we report here selectively summarized data as an overview of the 2006 follow-up survey of the registered cases from 1998 to 2004 for information bearing on problems with the treatment of cancer of the biliary tract. A total of 5,584 patients were registered from 1998 to 2004. The site of cancer was the bile duct in 2,732 patients, the gallbladder in 2,067, and the papilla of Vater in 785. Those cases were analyzed with regard to patient survival according to the extent of tumor invasion (pT), the extent of lymph node metastasis (pN) and the stage. The five-year survival rate after surgical resection was 33.1% for bile duct cancer, 41.6% for gallbladder cancer, and 52.8% for cancer of the papilla of Vater. For hilar or superior bile duct cancer, the 5-year survival rate was lower with an increase in the pT, pN and f stage, except pT3 vs. pT4, pN1 vs. pN2 and stage III vs. stage IVa. For middle or distal bile duct cancer, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT2 vs. pT3, pN2 vs. pN3, stage II vs. stage III and stage III vs. stage IVa. For gallbladder cancer, the 5-year survival rate was lower with increase in pT, pN and f stage. For cancer of the papilla of Vater, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT1 vs. pT2, pN1 vs. pN2, and stage III vs. stage IVa. In the present study, the outcomes of surgical treatment were better than that of the previous report from Japan and foreign countries. The pT, pN and stage of gallbladder cancer are well defined. However, there were no significant differences in some groups of those of bile duct cancer and cancer of the papilla of Vater.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [41] Biliary tract cancers:: From pathogenesis to endoscopic treatment
    Demols, Anne
    Marechal, Raphael
    Deviere, Jacques
    Van Laethem, Jean-Luc
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2007, 21 (06) : 1015 - +
  • [42] Exome sequencing of 22 genes using tissue from patients with biliary tract cancer
    Hogdall, Dan
    Larsen, Ole F.
    Linnemann, Dorte
    Poulsen, Tim Svenstrup
    Hogdall, Estrid, V
    APMIS, 2020, 128 (01) : 3 - 9
  • [43] Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Tober, Nastassja
    Nigro, Maria Concetta
    Mosca, Mirta
    Palloni, Andrea
    Abbati, Francesca
    Frega, Giorgio
    De Lorenzo, Stefania
    Tavolari, Simona
    Brandi, Giovanni
    ANTICANCER RESEARCH, 2020, 40 (06) : 3013 - 3030
  • [44] Preliminary Experience of Cetuximab in the Treatment of Advanced-Stage Biliary Tract Cancer
    Chang, Ping-Ying
    Cheng, Ming-Fang
    Lee, Herng-Sheng
    Hsieh, Chung-Bao
    Yao, Nai-Shun
    ONKOLOGIE, 2010, 33 (1-2): : 45 - 47
  • [45] Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Cusmai, Antonio
    Acquafredda, Silvana
    De Palma, Giuseppe
    Brandi, Giovanni
    Palmiotti, Gennaro
    CURRENT ONCOLOGY, 2022, 29 (02) : 551 - 564
  • [46] Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer
    Alexander, Shaun
    Aleem, Umair
    Jacobs, Timothy
    Frizziero, Melissa
    Foy, Victoria
    Hubner, Richard A.
    McNamara, Mairead G.
    CANCERS, 2024, 16 (19)
  • [47] Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
    Makoto Ueno
    Masafumi Ikeda
    Takashi Sasaki
    Fumio Nagashima
    Nobumasa Mizuno
    Satoshi Shimizu
    Hiroki Ikezawa
    Nozomi Hayata
    Ryo Nakajima
    Chigusa Morizane
    BMC Cancer, 20
  • [48] Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
    Ueno, Makoto
    Ikeda, Masafumi
    Sasaki, Takashi
    Nagashima, Fumio
    Mizuno, Nobumasa
    Shimizu, Satoshi
    Ikezawa, Hiroki
    Hayata, Nozomi
    Nakajima, Ryo
    Morizane, Chigusa
    BMC CANCER, 2020, 20 (01)
  • [49] Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
    Okusaka, T.
    Nakachi, K.
    Fukutomi, A.
    Mizuno, N.
    Ohkawa, S.
    Funakoshi, A.
    Nagino, M.
    Kondo, S.
    Nagaoka, S.
    Funai, J.
    Koshiji, M.
    Nambu, Y.
    Furuse, J.
    Miyazaki, M.
    Nimura, Y.
    BRITISH JOURNAL OF CANCER, 2010, 103 (04) : 469 - 474
  • [50] Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis
    Dodoo, Grace N.
    De, Brian
    Lee, Sunyoung S.
    Jaoude, Joseph Abi
    Vauthey, Jean-Nicolas
    Tzeng, Ching-Wei D.
    Cao, Hop S. Tran
    Katlowitz, Kalman A.
    Mandel, Jacob J.
    Beckham, Thomas H.
    Minsky, Bruce D.
    Smith, Grace L.
    Holliday, Emma B.
    Koong, Albert C.
    Das, Prajnan
    Taniguchi, Cullen M.
    Javle, Milind
    Koay, Eugene J.
    Ludmir, Ethan B.
    ONCOLOGIST, 2023, : 327 - 332